Global Cutaneous Leishmaniasis Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Cutaneous Leishmaniasis Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Cutaneous leishmaniasis is the most common syndrome and can produce ulcers that have the potential of stimulating a periosteal reaction if the ulcer occurs near bone.
Leishmaniasis, a protozoal infection transmitted by sandfly bite, produces a clinical spectrum of disease ranging from asymptomatic infection to ulcerative skin and mucosal lesions to visceral involvement. Leishmaniasis is endemic in regions of Africa, the Middle East, south Asia, southern Europe, northern South America, and Central America. There has been an increase in imported leishmaniasis into developed, non-endemic countries due to increasing global travel. While pentavalent antimonials have been the mainstay of antileishmanial treatment for decades, newer therapeutic options have become available for all forms of infection, including liposomal amphotericin B, miltefosine, fluconazole, and ketoconazole.
Cutaneous Leishmaniasis Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cutaneous Leishmaniasis Drugs market is projected to reach US$ 57 million in 2034, increasing from US$ 43 million in 2022, with the CAGR of 4.1% during the period of 2024 to 2034. Demand from Hospital and Retail Pharmacy are the major drivers for the industry.
Global Cutaneous Leishmaniasis Drugs Sales key players include Sanofi, Albert David, Albert David, etc. Global top three manufacturers hold a share over 60%. Middle East and Africa is the largest market, with a share about 40%, followed by Asia-Pacific, and South America. In terms of product, Pentavalent Antimonials is the largest segment, with a share over 43%. In Cutaneous Leishmaniasis Drugs market, the Hospital holds an important share in terms of Application, followed by Retail Pharmacy, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cutaneous Leishmaniasis Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
GSK
Novartis
Sanofi
Gilead Sciences
Bristol-Myers Squibb
Albert David
Profounda
Knight Therapeutics
Pfizer
Xinhua Pharma
Segment by Type
Pentavalent Antimonials
Antifungal Drugs
Anti-Leishmanial/Antimicrobial Drugs
Hospital
Retail Pharmacy
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cutaneous Leishmaniasis Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cutaneous Leishmaniasis Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cutaneous Leishmaniasis Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Cutaneous Leishmaniasis Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cutaneous Leishmaniasis Drugs introduction, etc. Cutaneous Leishmaniasis Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Cutaneous Leishmaniasis Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Leishmaniasis, a protozoal infection transmitted by sandfly bite, produces a clinical spectrum of disease ranging from asymptomatic infection to ulcerative skin and mucosal lesions to visceral involvement. Leishmaniasis is endemic in regions of Africa, the Middle East, south Asia, southern Europe, northern South America, and Central America. There has been an increase in imported leishmaniasis into developed, non-endemic countries due to increasing global travel. While pentavalent antimonials have been the mainstay of antileishmanial treatment for decades, newer therapeutic options have become available for all forms of infection, including liposomal amphotericin B, miltefosine, fluconazole, and ketoconazole.
Cutaneous Leishmaniasis Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cutaneous Leishmaniasis Drugs market is projected to reach US$ 57 million in 2034, increasing from US$ 43 million in 2022, with the CAGR of 4.1% during the period of 2024 to 2034. Demand from Hospital and Retail Pharmacy are the major drivers for the industry.
Global Cutaneous Leishmaniasis Drugs Sales key players include Sanofi, Albert David, Albert David, etc. Global top three manufacturers hold a share over 60%. Middle East and Africa is the largest market, with a share about 40%, followed by Asia-Pacific, and South America. In terms of product, Pentavalent Antimonials is the largest segment, with a share over 43%. In Cutaneous Leishmaniasis Drugs market, the Hospital holds an important share in terms of Application, followed by Retail Pharmacy, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cutaneous Leishmaniasis Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
GSK
Novartis
Sanofi
Gilead Sciences
Bristol-Myers Squibb
Albert David
Profounda
Knight Therapeutics
Pfizer
Xinhua Pharma
Segment by Type
Pentavalent Antimonials
Antifungal Drugs
Anti-Leishmanial/Antimicrobial Drugs
Segment by Application
Hospital
Retail Pharmacy
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cutaneous Leishmaniasis Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cutaneous Leishmaniasis Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cutaneous Leishmaniasis Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Cutaneous Leishmaniasis Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cutaneous Leishmaniasis Drugs introduction, etc. Cutaneous Leishmaniasis Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Cutaneous Leishmaniasis Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices